Key Highlights

  • IDEXX shares are trading up 20.51% at $664.27, against a previous close of $551.21.
  • Adjusted EPS of $3.96 topped the $3.71 estimate, and Revenue rose 10%.
  • Full-year 2026 EPS guidance rose to $14.96 to $15.16.

IDEXX (NASDAQ:IDXX) shares are trading up 20.51% at $664.27, against a previous close of $551.21, after the company reported third-quarter results ahead of estimates and raised its full-year 2026 outlook. The rebound follows a slide of roughly 5% on Friday and comes on Volume well above average.

IDEXX, based in Westbrook, Maine, develops and distributes diagnostics, software and water testing products for pet healthcare, livestock, poultry and dairy customers in more than 175 countries. Its Companion Animal Group sells in-clinic analyzers such as Catalyst, ProCyte Dx and SediVue Dx, along with SNAP rapid tests and reference laboratory services, in a razor-and-blade model where an installed base of analyzers drives recurring consumable revenue.

Third-Quarter Results Beat Estimates

Third-quarter revenue rose 10% to about $1.21 billion, a 1.89% beat against estimates. Adjusted Earnings Per Share of $3.96 topped the $3.71 estimate, while EPS of $4.01 was up 18% as reported and 22% on a comparable basis. Operating Margin came in at 33.1%.

CAG Diagnostics Recurring Revenue grew 11% organically, with international growth near 14% and U.S. growth of 9.6%, including about 4% from net price. U.S. same-store clinical visits fell an estimated 1.8%, yet the company said growth was volume-led, driven by innovation and commercial execution.

Premium instrument placements reached 5,780 units, including 1,904 inVue Dx units and nearly 1,200 competitive and greenfield Catalyst placements. inVue Dx is on track to exceed its 5,500-unit goal for 2026, its installed base is near 11,000 units, and management expects to pass the 20,000-unit five-year goal.

Raised Guidance and Product Pipeline

IDEXX lifted full-year 2026 revenue guidance to between $4.741 billion and $4.767 billion, up $32 million at the midpoint, including about $5 million from the Covet acquisition. Organic revenue growth is now expected at 9.3% to 10%, and CAG Diagnostics recurring organic growth at 10.3% to 11%. EPS guidance rose to $14.96 to $15.16, up $0.25 at the midpoint, including about $0.13 of Covet dilution.

Full-year operating margin guidance was trimmed to 32.1% to 32.3%, with about 30 basis points of drag from Covet, and the fourth-quarter margin is guided to 28.4% to 29.3%. Free Cash Flow conversion is expected at 95% to 100% of net income, with Capital Expenditure of about $160 million. Management expects margin expansion off these levels over the next 12 months, in line with its long-term goal of 50 to 100 basis points a year.

Fine needle aspirate testing is now available to all North American customers, and revenue per analyzer remains within the $3,500 to $5,500 range. The stock trades on a trailing price-to-earnings ratio of 61.85 and a forward ratio of 41.16, with trailing earnings per share of $14.22.

In cancer diagnostics, which has more than 14,000 customers, mast cell tumor detection was added in September at the same price, and hemangiosarcoma detection is planned for broad North American availability in the first quarter of 2027. Covet, an AI clinical assistant with about $20 million in annualized revenue, joined the portfolio, and the Catalyst Pro BMP panel launched.

Capital Returns and What to Watch

Share repurchases total $805 million year to date. Leerink reiterated its Outperform rating, and the stock remains below its 52-week high of $769.98, with a 52-week low of $500.61.

The quarter showed placements and recurring revenue growing even as clinic visit traffic softened. The next checkpoints are whether visit trends stabilize, how much margin expansion appears over the next 12 months, and how the market receives the MultiQ DX platform, which management will detail at an investor event on Jan. 18.